ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1869

Analysis of Short-Term Side Effects Following COVID-19 Vaccination in Pregnancies Complicated by Autoimmune Inflammatory Rheumatic Diseases
Abstract Number: 2126

Analysis of the Evolution of Bone Mineral Density in the Spanish Population: Results of the OsteoSER Study
Abstract Number: 0335

Analysis of the Prevalence of Diabetes Mellitus in Patients with Adult-onset Dermatomyositis
Abstract Number: 0553

Analyzing the Utilization of HLA-B27 Testing in a Large Rural Health System: Implications for Diagnostic Appropriateness
Abstract Number: 2492

ANCA Associated Tracheobronchial Disease
Abstract Number: 2690

ANCA IgG Promotion of Neutrophil Recruitment, Migration and Vascular Damage in ANCA Associated Vasculitis May Be Enhanced by Hypoxia
Abstract Number: 0735

ANCA-associated Vasculitis (AAV) and Long-term Risk of Cardiovascular Disease: Large-scale Propensity-matched Global Retrospective Cohort Study
Abstract Number: 1272

Angiopoietin-2 and Soluble Tumor Necrosis Factor Receptor Type II Are Elevated in Treatment Naïve JDM Plasma and Associate with Increased Muscle Disease Activity and Decreased Nailfold Capillary Density
Abstract Number: 2424

Anifrolumab Effects on Response to Influenza Vaccine in SLE
Abstract Number: 1548

Anifrolumab in Systemic Lupus Erythematosus. Spanish National Registry in a Real-world Setting
Abstract Number: L13

Anifrolumab Long-Term Treatment Is More Effective Against Organ Damage Than Standard of Care Alone: Results from an External Control Arm Study on Organ Damage in Phase 3 Clinical Trials and the University of Toronto Lupus Clinic Cohort
Abstract Number: 1776

Animal Models of Pediatric MOGAD
Abstract Number: 1056

Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis
Abstract Number: 0035

Anti-CCP Generation in the Female Genital Tract Is Increased During the Postpartum Period in Women Without RA
Abstract Number: 2427

Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Induces Multicompartmental B Cell Depletion in Peripheral Blood, Bone Marrow and Lymph Nodes of Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].